Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Evofem Biosciences, Inc. (EVFM)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Total revenues | 2.5 | 5.8 | 0.2 | 6.4 | 6.0 | 4.3 | 3.6 | 1.7 |
| Revenue growth | -59.3% | 36.7% | -94.9% | 272.1% | 224.9% | 284.7% | 2025.0% | 515.8% |
| Cost of goods sold | 2.3 | 1.4 | 0.4 | 1.7 | 1.3 | 1.1 | 1.8 | 1.0 |
| Gross profit | 0.2 | 4.4 | -0.2 | 4.7 | 4.7 | 3.2 | 1.8 | 0.8 |
| Gross margin | 6.7% | 76.3% | -112.2% | 73.6% | 78.7% | 74.9% | 50.8% | 44.2% |
| Selling, general and administrative [+] | 7.1 | 7.5 | 10.2 | 18.2 | 21.4 | 21.7 | 30.6 | 35.4 |
| Sales and marketing | 2.2 | 3.9 | 7.0 | 11.9 | 12.3 | 12.7 | 24.9 | 30.5 |
| General and administrative | 4.9 | 3.6 | 3.2 | 6.3 | 9.1 | 9.0 | 5.7 | 5.0 |
| Research and development | 0.4 | 0.5 | 1.7 | 5.2 | 7.7 | 10.4 | 8.7 | 8.7 |
| EBITDA [+] | -7.2 | -3.3 | -11.8 | -18.5 | -24.2 | -28.7 | -37.1 | -43.1 |
| EBITDA growth | -70.4% | -88.4% | -68.2% | -57.1% | -40.9% | -35.8% | 3.9% | 65.2% |
| EBITDA margin | -291.4% | -57.4% | -6520.4% | -290.0% | -400.5% | -674.3% | -1040.1% | -2517.6% |
| Depreciation and amortization | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| EBIT [+] | -7.3 | -3.6 | -12.1 | -18.7 | -24.4 | -28.9 | -37.4 | -43.4 |
| EBIT growth | -70.0% | -87.6% | -67.8% | -56.8% | -40.6% | -35.5% | 4.4% | 65.8% |
| EBIT margin | -298.5% | -61.6% | -6658.6% | -293.9% | -404.7% | -680.5% | -1048.1% | -2533.2% |
| Interest expense, net [+] | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expense | 0.6 | 0.6 | 0.6 | | 0.5 | 0.5 | 0.5 | |
| Interest income | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.7 | 1.8 | 4.3 | 108.2 | -101.0 | -2.4 | -13.6 | -30.7 |
| Other | -1.1 | -0.3 | -0.8 | -0.4 | -0.4 | -0.5 | -1.2 | -1.2 |
| Pre-tax income | -8.6 | -2.4 | -8.3 | 89.5 | -126.0 | -31.9 | -51.5 | -74.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | | | | 0.0% |
| Net income | -8.6 | -2.4 | -11.5 | 89.5 | -124.1 | -32.0 | -52.6 | -74.1 |
| Net margin | -348.2% | -40.5% | -6342.0% | 1404.9% | -2056.2% | -752.0% | -1473.4% | -4326.0% |
| |
| Basic EPS [+] | ($5.43) | ($1.85) | ($0.20) | $1.09 | ($571.69) | ($360.25) | ($6.03) | ($7.20) |
| Growth | -99.1% | -99.5% | -96.7% | -115.1% | 14171.8% | 4159.1% | 897.0% | 1855.9% |
| Diluted EPS [+] | ($5.43) | ($1.85) | ($0.20) | $0.16 | ($571.69) | ($360.25) | ($6.03) | ($7.20) |
| Growth | -99.1% | -99.5% | -96.7% | -102.2% | 14171.8% | 4159.1% | 897.0% | 1855.9% |
| |
| Shares outstanding (basic) [+] | 1.6 | 1.3 | 58.2 | 82.4 | 0.2 | 0.1 | 8.7 | 10.3 |
| Growth | 626.2% | 1332.8% | 567.4% | 701.6% | -97.4% | -98.4% | -87.0% | -87.3% |
| Shares outstanding (diluted) [+] | 1.6 | 1.3 | 58.2 | 555.2 | 0.2 | 0.1 | 8.7 | 10.3 |
| Growth | 626.2% | 1332.8% | 567.4% | 5299.0% | -97.4% | -98.4% | -87.0% | -87.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|